Literature DB >> 24629838

Expression of stress ligands of the immunoreceptor NKG2D in melanoma: regulation and clinical significance.

Annette Paschen1, Jolanthe Baingo2, Dirk Schadendorf2.   

Abstract

Tumor cells, in particular melanoma cells, can be detected as abnormal self by cytotoxic lymphocytes of the innate and adaptive immune system. Of major importance in this process is the activating lymphocyte receptor NKG2D that in humans binds to MIC and ULBP surface molecules on tumor cells. Expression of NKG2D ligands (NKG2DL) is an early event in malignant transformation, induced by stress-associated and oncogene-driven pathways. Thus NKG2DL expression is considered as an innate barrier against tumor development. However, tumor cells can overcome this barrier by shedding of NKG2DL. Ligand shedding leads to elevated levels of soluble ligands in sera of tumor patients that in case of melanoma are of strong prognostic relevance. Here we review important aspects of NKG2DL expression and regulation in tumor cells with a focus on melanoma, and discuss their clinical relevance and potential in immunotherapy.
Copyright © 2014 Elsevier GmbH. All rights reserved.

Entities:  

Keywords:  Melanoma; NKG2D ligand; Tumor immune surveillance

Mesh:

Substances:

Year:  2014        PMID: 24629838     DOI: 10.1016/j.ejcb.2014.01.009

Source DB:  PubMed          Journal:  Eur J Cell Biol        ISSN: 0171-9335            Impact factor:   4.492


  10 in total

1.  Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study.

Authors:  Cristina Maccalli; Diana Giannarelli; Filippo Capocefalo; Lorenzo Pilla; Ester Fonsatti; Anna Maria Di Giacomo; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2015-08-12       Impact factor: 8.110

2.  Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome.

Authors:  Marie-Andrée Forget; Cara Haymaker; Kenneth R Hess; Yuzhong Jeff Meng; Caitlin Creasy; Tatiana Karpinets; Orenthial J Fulbright; Jason Roszik; Scott E Woodman; Young Uk Kim; Donastas Sakellariou-Thompson; Ankit Bhatta; Arely Wahl; Esteban Flores; Shawne T Thorsen; René J Tavera; Renjith Ramachandran; Audrey M Gonzalez; Christopher L Toth; Seth Wardell; Rahmatu Mansaray; Vruti Patel; Destiny Joy Carpio; Carol Vaughn; Chantell M Farinas; Portia G Velasquez; Wen-Jen Hwu; Sapna P Patel; Michael A Davies; Adi Diab; Isabella C Glitza; Hussein Tawbi; Michael K Wong; Suzanne Cain; Merrick I Ross; Jeffrey E Lee; Jeffrey E Gershenwald; Anthony Lucci; Richard Royal; Janice N Cormier; Jennifer A Wargo; Laszlo G Radvanyi; Carlos A Torres-Cabala; Rameen Beroukhim; Patrick Hwu; Rodabe N Amaria; Chantale Bernatchez
Journal:  Clin Cancer Res       Date:  2018-05-30       Impact factor: 12.531

3.  Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade.

Authors:  Joy Hsu; Jonathan J Hodgins; Malvika Marathe; Chris J Nicolai; Marie-Claude Bourgeois-Daigneault; Troy N Trevino; Camillia S Azimi; Amit K Scheer; Haley E Randolph; Thornton W Thompson; Lily Zhang; Alexandre Iannello; Nikhita Mathur; Karen E Jardine; Georgia A Kirn; John C Bell; Michael W McBurney; David H Raulet; Michele Ardolino
Journal:  J Clin Invest       Date:  2018-09-10       Impact factor: 14.808

Review 4.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

5.  Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients.

Authors:  Cristina Maccalli; Diana Giannarelli; Carla Chiarucci; Ornella Cutaia; Gianluca Giacobini; Wouter Hendrickx; Giovanni Amato; Diego Annesi; Davide Bedognetti; Maresa Altomonte; Riccardo Danielli; Luana Calabrò; Anna Maria Di Giacomo; Francesco M Marincola; Giorgio Parmiani; Michele Maio
Journal:  Oncoimmunology       Date:  2017-05-08       Impact factor: 8.110

6.  Protein Signatures of NK Cell-Mediated Melanoma Killing Predict Response to Immunotherapies.

Authors:  Sabrina Cappello; Hsu-Min Sung; Christian Ickes; Christine S Gibhardt; Adina Vultur; Hilal Bhat; Zhongwen Hu; Patricia Brafford; Andreas Denger; Ioana Stejerean-Todoran; Rixa-Mareike Köhn; Verena Lorenz; Nicolas Künzel; Gabriela Salinas; Hedwig Stanisz; Tobias Legler; Peter Rehling; Michael P Schön; Karl S Lang; Volkhard Helms; Meenhard Herlyn; Markus Hoth; Carsten Kummerow; Ivan Bogeski
Journal:  Cancer Res       Date:  2021-09-13       Impact factor: 12.701

Review 7.  Sensing Bacterial-Induced DNA Damaging Effects via Natural Killer Group 2 Member D Immune Receptor: From Dysbiosis to Autoimmunity and Carcinogenesis.

Authors:  J Luis Espinoza; Mika Minami
Journal:  Front Immunol       Date:  2018-01-25       Impact factor: 7.561

Review 8.  Role of Distinct Natural Killer Cell Subsets in Anticancer Response.

Authors:  Helena Stabile; Cinzia Fionda; Angela Gismondi; Angela Santoni
Journal:  Front Immunol       Date:  2017-03-16       Impact factor: 7.561

9.  Expanded NK cells from umbilical cord blood and adult peripheral blood combined with daratumumab are effective against tumor cells from multiple myeloma patients.

Authors:  Chantal Reina-Ortiz; Michael Constantinides; Alexis Fayd-Herbe-de-Maudave; Jessy Présumey; Javier Hernandez; Guillaume Cartron; David Giraldos; Rosana Díez; Isabel Izquierdo; Gemma Azaceta; Luis Palomera; Isabel Marzo; Javier Naval; Alberto Anel; Martín Villalba
Journal:  Oncoimmunology       Date:  2020-12-29       Impact factor: 8.110

Review 10.  Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges.

Authors:  Lorenzo Pilla; Cristina Maccalli
Journal:  Biomedicines       Date:  2018-07-02
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.